Miltefosine - Endo International

Drug Profile

Miltefosine - Endo International

Alternative Names: D 18506; HePC; Hexadecylphosphocholine; HPC; Impavido; Miltefosin; Miltex

Latest Information Update: 04 Jul 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Baxter Oncology; Zentaris
  • Developer AEterna Zentaris GmbH; Knight Therapeutics; MegaPharm Ltd; Profounda
  • Class Antineoplastics; Antiparasitics; Phospholipids; Quaternary ammonium compounds
  • Mechanism of Action Signal transduction pathway inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Encephalitis; Acanthamoeba infections; Visceral leishmaniasis
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Cancer metastases; Cutaneous leishmaniasis; Leishmaniasis; Visceral leishmaniasis
  • Preclinical Acanthamoeba infections
  • No development reported Chagas disease
  • Discontinued Malignant melanoma

Most Recent Events

  • 28 Jun 2017 Miltefosine receives Orphan Drug status for Granulomatous amebic encephalitis in USA
  • 19 Dec 2016 Preclinical trials in Acanthamoeba infections in USA (unspecified route)
  • 19 Dec 2016 Miltefosine receives Orphan Drug status for Acanthamoeba keratitis in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top